Reprocell USA, a contract research organization (CRO), has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)”.

The Harmonic study is being conducted to determine clinical advantages for Lantern Pharma’s investigational new drug LP-300 in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors (TKIs). 

Reprocell will produce Specimen Collection Kits, process patient samples and store biomaterial from patients in this study.  In addition, Reprocell will provide isolation of cell free DNA from plasma, genomic DNA and/or RNA from the buffy coat fraction, and archive pathology FFPEs and associated H&E-stained slides from selected patients. These services are routine procedures utilized at Reprocell and will be performed at the conclusion of specimen collection and processing. Reprocell will retain all biomaterials and pathology materials on-site until required by Lantern Pharma.

“We are excited to select Reprocell to support our Phase 2 Harmonic trial for never smokers with advanced non-small cell lung cancer,” said Reggie Ewesuedo, Lantern’s vice president of Clinical Development. “Reprocell has an excellent and proven track record of processing and storing clinical trial samples and we are confident that this partnership will further the advancement of the Harmonic trial.”

“We are pleased to support Lantern Pharma in the Harmonic clinical trial.  We believe that our capabilities in building kits, managing shipments to and from clinical sites and processing the bio samples will help Lantern Pharma in successfully conducting this trial,” said Rama Modali, CEO, Reprocell, USA.